Here you can take take a self competency review test on Drug Regulatory Affairs. Regulatory Affairs review test is mcq type assessment test where you can check your regulatory skills.... Read More
Torrent Pharmaceuticals Ltd will acquire dermatology company Curatio Health Care India Pvt Ltd for ₹2,000 crore. The consideration includes ₹115 crore (on the date of signing) of cash and cash equivalents... Read More
Pfizer entered into a definitive agreement under which Pfizer will acquire Biohaven for 11.6 billion $. Biohen is the maker of Nurtec ODT, an innovative dual-acting migraine therapy approved for... Read More
Aurobindo Pharma Ltd has announced the acquisition of the domestic formulation business of Veritaz Healthcare for a consideration of Rs. 171 crore on debt-free cash-free basis. With this acquisition, Aurobindo... Read More
Sun Pharma has entered into an exclusive patent licensing agreement with H. Lundbeck A/S (“Lundbeck”) to market and distribute its own version of Vortioxetine in India under the brand name,... Read More
HEOR and market access are the two separate domain or functional area within pharmaceutical organization. But they work for the same or similar objective. Both are having objective to gain... Read More
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the US Food and Drug Administration (FDA) has approved Ztalmy (ganaxolone)... Read More
Lynk Pharmaceuticals Co., Ltd. and Simcere announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China. Under the terms of the agreement, Lynk Pharmaceuticals... Read More
Design of experiments (DoE) is a systematic approach aiming to maximize information content from an experimental study, while keeping the number of experiments low. During formulation development, DoE is used... Read More
Torrent Pharmaceuticals Limited (TPL) has announced that it has signed a non-exclusive, non-transferable, non-sub licensable, license agreement to use the patents and know-how in relation to the compound nirmatrelvir with... Read More
AstraZeneca launched a global R&D Postdoctoral Challenge to help accelerate ideas to transform the treatment of some of the world’s most complex diseases. AstraZeneca launches this initiative at EXPO 2020... Read More
Pfizer will acquire Arena Pharmaceuticals for $6.7 billion to expand its pipeline of immuno-inflammatory disease drugs in development. Why Pfizer acquired Arena? The proposed acquisition of Arena complements Pfizer’s capabilities... Read More
Zydus Cadila said its antimalarial compound ZY19489′, which is currently under development with Medicines for Malaria Venture (MMV), has received ‘orphan drug designation’ from the US FDA. The orphan drug... Read More
Keros Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need,... Read More
NATCO Pharma, through its affiliates, is proposing to enter into an agreement to acquire Dash Pharmaceuticals LLC subject to satisfactory completion of due diligence, execution of definitive agreements and compliance... Read More
Drug major Cadila Pharmaceuticals has introduced an ayurvedic general health tonic that helps keep the body young, active and fit. The key ingredients of Healtherbs include Gokhru (Tribulus terrestris), Ashwagandha... Read More
Cipla Limited announced a first-of-its-kind initiative to improve access to nebulization therapy specifically for patients in the rural sections of the country. With Cipla’s unmatched presence across the care continuum... Read More
Swedish life science company Aqilion has acquired all rights to Regulus, a Phase I-ready anti-inflammatory program, from Denmark-headquartered dermatology specialist LEO Pharma, which developed the project from early internal discovery... Read More
Sun Pharma Advanced Research Company (SPARC) has entered into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target. Biomodifying, LLC is a biotech company... Read More
Merck will acquire Acceleron Pharma, Inc. XLRN for $180 per share in cash for an approximate total equity value of $11.5 billion in a bid to build its rare diseases... Read More
This website uses cookies to improve your learning experience. OkPrivacy Policy
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.